Is Endonovo Therapeutics, Inc. (ENDV) a Buy, Sell, or Hold?
OTC : ENDV
Endonovo Therapeutics, Inc.
$0.0001 USD
$0 (0.0%)
- Volume
- 990K
- Average Volume
- 393.06K
- Market Capitalization
- $31.88K
- P/E Ratio
- 1.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.00
Company Overview
OTC
Alan Brian Collier
Biotechnology
Healthcare
ENDV
1
US
USD
Liquidity Metrics
-0.24
0.00
0.00
0.00
0.00
Sales & Valuation
-$
0.00
-0.01
-0.47
0.00
Profitability
-$0.0012
-$2.18M
0.00%
0.00%
7.79%
-11338.08%
P/E Metrics
1.00
0.00
0.00
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-7213.00
2/9
-$29.38M
$19665.0
$29.48M
-$992.27K
Key Metrics (TTM)
$7M
0.00
-7.05
0.00
7.79%
4.43%
-1233.51%
-212.08%
0 days
Company Executives
| Name | Title |
|---|---|
| Garry Michael Kann | Head of Corporate Development |
| Don Calabria | Vice President of Operations |
| Alan Brian Collier | Chairman & Chief Executive Officer |
| Ira Weisberg | President & Chief Commercial Officer of Medical Division |
Poll Results
No votes yet today — be the first to share your view!
About Endonovo Therapeutics, Inc. (OTC:ENDV) Stock
Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), periphera ... l artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.
Frequently Asked Questions
-
What is the current Endonovo Therapeutics, Inc. (ENDV) stock price?
-
Endonovo Therapeutics, Inc.(OTC:ENDV) stock price is $0.0001 in the last trading session. During the trading session, ENDV stock reached the peak price of $0.0002 while $0.00005 was the lowest point it dropped to. The percentage change in ENDV stock occurred in the recent session was 0.0% while the dollar amount for the price change in ENDV stock was $0.
-
ENDV's industry and sector of operation?
-
The OTC listed ENDV is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ENDV?
-
Garry Michael Kann | Head of Corporate Development
Don Calabria | Vice President of Operations
Alan Brian Collier | Chairman & Chief Executive Officer
Ira Weisberg | President & Chief Commercial Officer of Medical Division
| -
How many employees does ENDV have?
-
Number of ENDV employees currently stands at 1. ENDV operates from 6320 Canoga Avenue, Woodland Hills, CA 91367, US.
-
Link for ENDV official website?
-
Official Website of ENDV is: https://www.endonovo.com
-
How do I contact ENDV?
-
ENDV could be contacted at phone #800 489 4774 and can also be accessed through its website. ENDV operates from 6320 Canoga Avenue, Woodland Hills, CA 91367, US.
-
How many shares of ENDV are traded daily?
-
The average number of ENDV shares traded daily for last 3 months was 393.06K.
-
What is the market cap of ENDV currently?
-
The market value of ENDV currently stands at $31.88K with its latest stock price at $0.0001